Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, ...
*Cost Savings are calculated using FY 2021 results as base year. The Company is not able to reconcile its forward-looking non-GAAP adjusted operating profit margin because the Company cannot predict ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback